Sanfilippo syndrome type A: Research & Drug Discovery Data

Drug discovery

drugs

With orphan designations

Overview

Sanfilippo syndrome type A (MPS IIIA) is a rare, fatal autosomal recessive lysosomal storage disorder caused by SGSH gene mutations, leading to sulfamidase deficiency and heparan sulfate accumulation. Initial symptoms (speech/developmental delays, hyperactivity, sleep disturbances) emerge in early childhood, followed by severe neurodegeneration, cognitive decline, and premature death (average lifespan 15–18 years) [1][6][12]. No curative treatments exist, though gene therapy trials show early promise [1][18].

Population

Incidence ranges from ~1/100,000 live births (Australia) to ~1/280,000 (Northern Ireland), making it the most common Sanfilippo subtype globally. Median diagnosis occurs at 3.5–4.9 years [2][7][12].

Burden

Estimated U.S. economic burden exceeds $2.04 billion (2023–2043), with families facing >$8 million/child in direct/indirect costs. Mortality primarily results from CNS complications or pneumonia, while caregivers experience elevated depression/anxiety rates [4][9][14][19].

Therapies

Investigational gene therapies (e.g., UX111/ABO-102, AAV9 vector) aim to restore sulfamidase activity, demonstrating reduced heparan sulfate levels and neurocognitive stabilization in early-phase trials [1][16][18].
Supportive care includes seizure management, physical/behavioral therapies, and palliative interventions [2][6][13].

Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases, rare ophthalmic disorders, rare transplant-related disorders

Research Papers

268 drug discovery papers related to Sanfilippo syndrome type A, with 4 first-in-class and 0 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-04-29 | Short-Term Oral Spermidine Supplementation Modifies Aspects of Neurodegenerative Disease in Flies and Mice With MPS III.

Mucopolysaccharidosis type III (MPS III) is a group of autosomal recessive neurodegenerative lysosomal storage disorders that causes progressive cognitive and physical impairment, predominantly in child/early adulthood. The median age of death is 17 years as there is no safe, effective treatment approved. Using faithful Drosophila and murine models of MPS III, we have characterised the MPS IIIA and MPS IIIC fly metabolome, explored the ability of oral spermidine supplementation to ameliorate clinical disease in the fly models and explored its mechanism of action in MPS IIIA mice. Spermidine is a polyamine naturally synthesised by the body. Its manufacture decreases with age. Supplementation has been reported to stimulate autophagy, reduce cell senescence and increase health/lifespan. The metabolomic evaluation confirmed that whole MPS IIIA and MPS IIIC flies exhibit a progressively deranged metabolome. Significantly up-regulated metabolites were those involved in nucleotide and purine metabolism. The most significantly down-regulated metabolites were those involved in ascorbate and aldarate metabolism. Further, spermidine levels decreased significantly in all fly genotypes with age. In short-term studies, food enriched with 5 mM spermidine improved overall fly activity and climbing ability. A 4-week study in pre-symptomatic MPS IIIA mice (3- or 6-mM spermidine, supplemented in drinking water) revealed no improvement in microgliosis or lysosomal compartment size; however, we observed a significant reduction in the astroglial response in the brain, which is believed to drive disease progression. Longer-term confirmatory studies in larger cohorts of MPS III animals are now warranted to determine whether spermidine supplementation is of benefit in preventing or slowing clinical disease in this and other childhood dementias.

Open article ↗

2026-04-08 | Modelling synaptic dysfunction in childhood dementia using human iPSC-derived cortical networks.

Alterations in synaptic homeostasis are linked to cognitive and behavioural impairments in brain disorders. However, synaptic dysfunction in childhood dementia is poorly understood. Here, we generate human cortical circuits from induced pluripotent stem cells (iPSCs) derived from donors with Mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo syndrome, a common form of childhood-onset dementia. Action potential firing capacity and morphology of MPS IIIA patient neurons in culture are similar to those of neurons from neurotypical donors. However, long-term neural maturation reveals excitation/inhibition imbalances caused by hyperactive excitatory synapses, disrupted network dynamics, and dysregulated gene expression linked to synaptic homeostasis. This study validates in vitro human neural models to detect neurophysiological phenotypes in childhood dementias and supports drug discovery strategies that target synaptic dysfunction to improve cognition in MPS IIIA and related brain disorders.

Open article ↗

2026-03-31 | RNA-seq dataset of brain tissue from MPSIIIA (Sgsh D31N) mouse model following antisense oligonucleotide treatment

This dataset contains RNA sequencing (RNA-seq) data generated from brain tissue of a murine model of mucopolysaccharidosis type IIIA (MPSIIIA). The model used was B6.Cg-Sgsh^MPSIIIA/PstJ mice (Jackson Laboratories), which harbor a missense mutation in the murine Sgsh gene (c.91G>A, p.D31N). Homozygous mice exhibit approximately 3–4% of normal SGSH enzymatic activity, resulting in extensive lysosomal accumulation of heparan sulfate (HS) and progressive neurodegeneration. RNA was extracted from brain tissue of wild-type, disease-model (Sgsh homozygous), and antisense oligonucleotide (ASO)-treated mice. RNA-seq libraries were prepared using the MARS-seq protocol and sequenced on an Illumina NovaSeq platform, generating single-end reads (~26 million reads per sample). Raw sequencing data are provided as FASTQ files, along with accompanying sample metadata. This dataset enables analysis of differential gene expression and transcriptional signatures associated with MPSIIIA pathology, as well as transcriptional changes following ASO-mediated reduction of EXT1 expression. The dataset is associated with the study:“Antisense oligonucleotides mediated substrate reduction therapy ameliorates heparan sulfate accumulation in MPSIIIA models. All animal procedures were approved by the Sheba Medical Center IACUC.

Open article ↗

2026-04-29 | Short-Term Oral Spermidine Supplementation Modifies Aspects of Neurodegenerative Disease in Flies and Mice With MPS III.

Open article ↗

2026-04-08 | Modelling synaptic dysfunction in childhood dementia using human iPSC-derived cortical networks.

Open article ↗

2026-03-31 | RNA-seq dataset of brain tissue from MPSIIIA (Sgsh D31N) mouse model following antisense oligonucleotide treatment

Open article ↗

Access all drug discovery articles and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

22 orphan drug designations for Sanfilippo syndrome type A.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
N-sulfoglucosamine sulfohydrolase	proteins	FDA	2024-02-20	—	Denali Therapeutics Inc.
Human heparan N-sulfatase, recombinant	proteins	EMA	2024-01-12	—	3R Pharma Consulting GmbH
Human N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor	proteins	FDA	2023-12-12	—	JCR Pharmaceuticals Co., Ltd.
recombinant self-complementary adeno-associated virus9 gene therapy expressing codon-optimized human N-Sulfoglucosamine Sulfohydrolase gene	gene therapies	FDA	2023-04-26	—	NeuroGT, Inc.
Recombinant Human Heparan N-sulfatase (rhHNS)	proteins	FDA	2023-01-24	—	GC Biopharma Corp.
N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor	proteins	EMA	2022-01-14	—	JCR Europe B.V.
Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein	proteins	FDA	2018-07-12	—	ArmaGen, Inc.
chemically modified recombinant sulfamidase	proteins	FDA	2017-06-28	—	Swedish Orphan Biovitrum AB (publ)
Autologous CD34+ hematopoietic stem cells transduced with an hCD11b lentiviral vector encoding for the human N-sulfoglucosamine sulfohydrolase (SGSH) gene	gene therapies	FDA	2017-05-03	—	Orchard Therapeutics Ltd.
Chemically modified human recombinant sulfamidase	proteins	EMA	2016-10-14	—	Swedish Orphan Biovitrum AB (publ)
Self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene	gene therapies	EMA	2016-10-14	—	Ultragenyx Netherlands B.V.
recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase	gene therapies	FDA	2016-09-01	—	Research Institute at Nationwide Children's Hospital
adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	gene therapies	FDA	2015-11-18	—	LYSOGENE
Adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA	gene therapies	EMA	2014-12-16	—	LYSOGENE
Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene	gene therapies	EMA	2014-06-10	—	Orchard Therapeutics (Netherlands) B.V.
recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	gene therapies	FDA	2014-04-29	—	Ultragenyx Pharmaceutical Inc.
adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	gene therapies	FDA	2013-05-06	—	Lysogene
Adeno-associated viral vector serotype 9 containing the human sulfamidase gene	gene therapies	EMA	2011-06-21	—	Esteve Pharmaceuticals S.A.
adeno-associated virus vector serotype 9 expressing human sulfamidase	gene therapies	FDA	2011-06-01	—	Esteve Pharmaceuticals, S.A.
Adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase and sulfatase modifying factor 1 cDNAs	gene therapies	EMA	2010-09-20	—	LYSOGENE
Human heparan N-sulfatase, recombinant	proteins	EMA	2008-11-07	—	Shire Pharmaceuticals Ireland Limited
sulfamidase	gene therapies	FDA	2008-05-22	—	Shire Human Genetic Therapies, Inc.

Sanfilippo syndrome type A

Sanfilippo syndrome type A

Sanfilippo syndrome type A

Overview

Population

Burden

Therapies

Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases, rare ophthalmic disorders, rare transplant-related disorders

Research Papers

2026-04-29 | Short-Term Oral Spermidine Supplementation Modifies Aspects of Neurodegenerative Disease in Flies and Mice With MPS III.

2026-04-08 | Modelling synaptic dysfunction in childhood dementia using human iPSC-derived cortical networks.

2026-03-31 | RNA-seq dataset of brain tissue from MPSIIIA (Sgsh D31N) mouse model following antisense oligonucleotide treatment

2026-04-29 | Short-Term Oral Spermidine Supplementation Modifies Aspects of Neurodegenerative Disease in Flies and Mice With MPS III.

2026-04-08 | Modelling synaptic dysfunction in childhood dementia using human iPSC-derived cortical networks.

2026-03-31 | RNA-seq dataset of brain tissue from MPSIIIA (Sgsh D31N) mouse model following antisense oligonucleotide treatment

Drug Discovery Landscape

Updated: Aug 8, 2026